Go Pro
NYSE:OGN

Organon & Co. Q1 2026 Earnings Report

Organon & Co. logo
$13.70 +0.01 (+0.04%)
As of 10:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Organon & Co. EPS Results

Actual EPS
$0.71
Consensus EPS
$0.83
Beat/Miss
Missed by -$0.12
One Year Ago EPS
$1.02

Organon & Co. Revenue Results

Actual Revenue
$1.46 billion
Expected Revenue
$1.49 billion
Beat/Miss
Missed by -$27.54 million
YoY Revenue Growth
-3.50%

Organon & Co. Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Thursday, April 30, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Organon & Co.'s Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Organon & Co. Earnings Headlines

Organon & Co. (NYSE:OGN) Given Average Recommendation of "Reduce" by Analysts
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
Organon: A Merger-Arbitrage Hold With Limited Upside
See More Organon & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organon & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organon & Co. and other key companies, straight to your email.

About Organon & Co.

Organon & Co. (NYSE:OGN) is a global healthcare company focused on improving the health and well-being of women throughout their lives. Its women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as fertility treatments and medicines used in reproductive health.

The company also markets biosimilars and a portfolio of established medicines across areas including cardiovascular disease, respiratory conditions, dermatology, pain management and allergy. Its products are distributed in markets around the world, with a particular focus on expanding access to medicines in international and emerging markets.

Organon was established as an independent company through a spin-off from Merck & Co. in June 2021. The company is headquartered in Jersey City, New Jersey, and has operated under the leadership of Chief Executive Officer Kevin Ali since its separation from Merck.

View Organon & Co. Profile